Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2015-08-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
NCT06394206
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
NCT06691412
Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response
NCT03590886
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
NCT02457637
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
NCT05754385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Specific biopsy requirements for hepatic steatosis: qualified biopsy specimen within 6 months, \>5% hepatocytes show macrovesicular steatosis under HE staining and X10 microscope.
3. Willing to participate in the long-term follow-up and cooperative.
4. Able to provide informed consent file.
Exclusion Criteria
2. Patients are eligible for baseline analysis but not eligible for follow-up, if having any of the following condition:
1. Any end-stage liver disease.
2. Any malignant tumor.
3. Any congenital liver disease such as Wilson disease.
4. Any other serious disease of projected survival \< 5 years.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unimed Scientific Inc.
INDUSTRY
Fatty Liver and Alcoholic Liver Disease Study Group, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiangao Fan, MD
Role: PRINCIPAL_INVESTIGATOR
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhangzhou Zhengxing Hospital
Zhangzhou, Fujian, China
Shandong Provincial Hospital
Ji'nan, Shandong, China
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
Shanghai Xinhua Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ruidan Zheng, MD
Role: primary
Wanhua Ren, MD
Role: primary
Liangping Li, MD
Role: primary
Yuqiang Mi, MD
Role: primary
Fangping He, MD
Role: primary
Junping Shi, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HBV2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.